Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT06494787 Org: User:
Start: 08/01/24 End: 12/31/25 Due: 12/31/26

Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures

Phase: N/A Priority: Normal
NCT ID: NCT05869994 Org: User:
Start: 01/27/23 End: 07/01/24 Due: 07/01/25

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03190174 Org: User:
Start: 08/24/17 End: 12/02/21 Due: 12/02/22

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03886311 Org: User:
Start: 05/15/19 End: 07/31/31 Due: 07/31/32

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04535271 Org: User:
Start: 09/09/21 End: 03/30/29 Due: 03/30/30

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03778996 Org: User:
Start: 01/03/20 End: 03/31/28 Due: 03/31/29

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04165330 Org: User:
Start: 10/17/19 End: 03/31/28 Due: 03/31/29

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04535713 Org: User:
Start: 09/30/20 End: 12/31/25 Due: 12/31/26

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03138161 Org: User:
Start: 04/13/17 End: 07/31/31 Due: 07/31/32